Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Atara Biotherapeutics ( (ATRA) ) has shared an announcement.
On May 14, 2024, Atara Biotherapeutics entered into an underwriting agreement with TD Securities (USA) LLC for an underwritten registered direct offering of its common stock and pre-funded warrants, expected to generate approximately $16 million in gross proceeds. The company plans to use the net proceeds to support its biologics license application for tab-cel and for general corporate purposes, with the offering set to close on May 16, 2025.
The most recent analyst rating on (ATRA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.
Spark’s Take on ATRA Stock
According to Spark, TipRanks’ AI Analyst, ATRA is a Neutral.
Atara Biotherapeutics faces significant financial challenges despite its revenue growth. The company’s high liabilities and negative cash flows are major concerns. Technical indicators show mixed signals, indicating cautious market sentiment. Although recent corporate events provide some positive outlook, the overall financial instability keeps the score low.
To see Spark’s full report on ATRA stock, click here.
More about Atara Biotherapeutics
Average Trading Volume: 59,541
Technical Sentiment Signal: Sell
Current Market Cap: $39.4M
For an in-depth examination of ATRA stock, go to TipRanks’ Stock Analysis page.